Long-term value of lecanemab to individuals and families

IF 6.8 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-08-28 DOI:10.1002/trc2.70151

Bryan Tysinger, Yifan Wei, Hanke Heun-Johnson, Julie M. Zissimopoulos

{"title":"Long-term value of lecanemab to individuals and families","authors":"Bryan Tysinger, Yifan Wei, Hanke Heun-Johnson, Julie M. Zissimopoulos","doi":"10.1002/trc2.70151","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We used data from a nationally representative sample of middle aged and older Americans combined with data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) on AD progression and data on lecanemab treatment effects from Clarity AD clinical trials. We use dynamic microsimulation modeling to quantify the long-term health and economic value of lecanemab for persons living with AD and their care partners.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>We quantified five measures of value: quality of life of the persons living with AD and their care partners, medical costs, caregiving costs, and earnings, and estimated that lecanemab had a value of $21,398 relative to no treatment after 4 years and $37,943 after 10 years. Extending the treatment to 48 months resulted in a value of $42,821 relative to no treatment after 4 years and $95,311 after 10 years. Forty-eight months of a similar next-generation therapy but with 50% efficacy in slowing cognitive and functional decline resulted in a value of $82,116 relative to no treatment after 4 years and $189,691 after 10 years.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Over time, lecanemab treatment reduced medical costs, hours of care required from care partners, and improved quality of life. There is much value to be gained with next-generation treatments that have a larger impact on slowing decline. Considering a wider range of outcomes in future assessments will provide a more complete understanding of value to support decision making about treatment initiation and about reimbursement for payers.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>There is significant value of lecanemab for persons with mild cognitive impairment or mild dementia.</li>\n \n <li>Over time, lecanemab reduces medical costs, caregiver hours, and improves the quality of life of persons living with Alzheimer's disease (AD) and their care partners.</li>\n \n <li>A next-generation treatment for AD with similar features to lecanemab but higher efficacy, more than doubles the value.</li>\n \n <li>Assessing therapy value supports decision making by patients and their health-care providers.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 3","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70151","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation.

METHODS

We used data from a nationally representative sample of middle aged and older Americans combined with data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) on AD progression and data on lecanemab treatment effects from Clarity AD clinical trials. We use dynamic microsimulation modeling to quantify the long-term health and economic value of lecanemab for persons living with AD and their care partners.

RESULTS

We quantified five measures of value: quality of life of the persons living with AD and their care partners, medical costs, caregiving costs, and earnings, and estimated that lecanemab had a value of $21,398 relative to no treatment after 4 years and $37,943 after 10 years. Extending the treatment to 48 months resulted in a value of $42,821 relative to no treatment after 4 years and $95,311 after 10 years. Forty-eight months of a similar next-generation therapy but with 50% efficacy in slowing cognitive and functional decline resulted in a value of $82,116 relative to no treatment after 4 years and $189,691 after 10 years.

DISCUSSION

Over time, lecanemab treatment reduced medical costs, hours of care required from care partners, and improved quality of life. There is much value to be gained with next-generation treatments that have a larger impact on slowing decline. Considering a wider range of outcomes in future assessments will provide a more complete understanding of value to support decision making about treatment initiation and about reimbursement for payers.

Highlights

There is significant value of lecanemab for persons with mild cognitive impairment or mild dementia.
Over time, lecanemab reduces medical costs, caregiver hours, and improves the quality of life of persons living with Alzheimer's disease (AD) and their care partners.
A next-generation treatment for AD with similar features to lecanemab but higher efficacy, more than doubles the value.
Assessing therapy value supports decision making by patients and their health-care providers.

Abstract Image

查看原文本刊更多论文

lecanemab对个人和家庭的长期价值

对莱卡耐单抗对阿尔茨海默病（AD）患者及其护理伙伴的价值进行评估，为患者及其卫生保健提供者决定开始治疗提供了重要信息。方法：我们使用了来自全国具有代表性的中老年美国人样本的数据，结合阿尔茨海默病神经影像学倡议（ADNI）关于AD进展的数据和来自Clarity AD临床试验的lecanemab治疗效果的数据。我们使用动态微观模拟模型来量化lecanemab对AD患者及其护理伙伴的长期健康和经济价值。结果：我们量化了5项价值指标：阿尔茨海默病患者及其护理伙伴的生活质量、医疗费用、护理费用和收入，并估计莱卡耐单抗在4年后相对于未治疗的价值为21,398美元，在10年后相对于未治疗的价值为37,943美元。将治疗延长至48个月，4年后相对于不治疗的价值为42,821美元，10年后为95,311美元。48个月的类似新一代治疗，但在减缓认知和功能衰退方面有50%的疗效，相对于不治疗，4年后的价值为82,116美元，10年后的价值为189,691美元。随着时间的推移，lecanemab治疗降低了医疗费用、护理伙伴所需的护理时间，并提高了生活质量。对减缓衰老有更大影响的下一代治疗方法有很大价值。在未来的评估中考虑更广泛的结果将提供对价值更全面的了解，以支持有关治疗开始和付款人报销的决策。莱卡耐单抗对轻度认知障碍或轻度痴呆患者有显著价值。随着时间的推移，lecanemab降低了医疗费用和护理时间，并提高了阿尔茨海默病（AD）患者及其护理伙伴的生活质量。新一代治疗AD的药物与lecanemab具有相似的特征，但疗效更高，价值翻了一倍以上。评估治疗价值有助于患者及其卫生保健提供者做出决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.